understanding, preventing, and delaying egfr resistance in the era of osimertinib
Published 5 years ago • 6.9K plays • Length 20:18Download video MP4
Download video MP3
Similar videos
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
44:03
egfr: the challenge of primary and secondary resistance
-
20:24
targeted treatment with egfr tkis: front line options
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
20:35
tki-resistant egfr-mutant nsclc
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
24:58
strategies to prevent and overcome resistance to egfr-directed therapies in lung cancer
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
2:21
treatment of egfr nsclc after progression
-
16:35
heterogeneity of nsclc and precipitating oncogenic driver mutations
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
8:37
egfr mechanisms of resistance
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
21:35
long term management of egfr-mutant nsclc -tsao
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc
-
14:30
adjuvant therapy for egfr mutant nsclc
-
5:45
egfr tki sequencing